Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Corning | GitLab | Moderna | |
|---|---|---|---|
| Moat rating | narrow Corning's FY2025 Form 10-K (filed 12 February 2026) documents real protection in two places and hedges everywhere else. In Display it states flatly that 'We are the largest worldwide producer of glass substrates for flat panel displays' and credits a 'proprietary fusion manufacturing process, which we invented and is the cornerstone of our technology leadership in the display glass industry'; in Optical Communications it says 'We maintain a leadership position in the segment's principal product groups, which include carrier and enterprise networks'. But the Competition section opens on a company-wide concession - 'Some of these competitors are larger than we are, and some have broader product lines' - and closes that opening paragraph with 'There is no assurance that we will be able to maintain or improve our market position or competitive advantage', a hedge set over the five per-segment paragraphs that follow, the last of which has Life Sciences facing 'competition from large distributors that have pursued backward integration or introduced private label products'. In optical it expects 'industry consolidation, pricing pressure and competition for the innovation of new products' to persist. The risk factors add that Optical Communications and Display 'generate a significant amount of the Company's profits and cash flow' and are 'subject to pricing pressure', while the customer base is concentrated enough that customers 'may possess substantial leverage in negotiating contractual obligations' - the filing's own table puts two combined end customers at 28% of 2025 Optical Communications segment net sales, three at 59% of Display, two at 43% of Specialty Materials and three at 61% of Automotive. Protection that is genuine but confined to part of the portfolio, held against named larger rivals and customers with that much leverage, is narrow rather than wide. | narrow The FY2026 10-K (year ended 2026-01-31) shows real expansion inside the installed base: 118% Dollar-Based Net Retention, Base Customers up to 10,682 from 9,893, customers above $100,000 of ARR up to 1,456 from 1,229, and $1.0 million ARR customers "to 155 from 123, an increase of 26%". But the filing concedes "limited barriers to entry" and names "Microsoft Corporation, which owns GitHub" as principal competitor. Retention decelerates (130% FY2024, 123% FY2025, 118% FY2026), and since DBNR is reported "on a threshold basis of 130%," the FY2024 figure is a cap and the slide is steeper than it looks. Narrow, not wide: expansion must be re-won against a bundled hyperscaler. | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | intangibles ip What the filing keeps pointing at is invented process technology and the patent estate fencing it, not a network and not raw size. The FY2025 10-K repeats 'Patent protection is important to the segment's operations' word for word in four of its five reportable segments - Optical Communications, Specialty Materials, Automotive and Life Sciences - and gives Display a stronger variant, 'Patent protection and proprietary trade secrets are important to the Display segment's operations'. It reports about 11,375 unexpired patents owned worldwide at the end of 2025 (about 4,015 of them U.S.), about 370 U.S. and over 970 non-U.S. grants during 2025 and about 5,650 applications in process, and states 'We have historically enforced, and will continue to enforce, our intellectual property rights.' The single clearest asset is a process rather than a product - the fusion draw Corning says it invented and calls the cornerstone of its display-glass technology leadership, guarded in Display by 'proprietary trade secrets'. Even the cost advantage the filing claims in optical is sourced back to the same place: 'Our large-scale manufacturing experience, fiber process, technology leadership and intellectual property provide cost advantages relative to several of our competitors' - scale is described there as a consequence of the process, not the origin of the advantage, which is why this is an IP-and-know-how moat rather than a cost-scale one. The estate is broad rather than cliff-edged: 'no one patent is considered material to any segment', and about 740 worldwide patents, 6.5% of the portfolio, expire between 2026 and 2028. | switching costs Stickiness comes from platform embedding, not IP. The 10-K rests differentiation on "our single platform with a unified data model," on "Consolidation of multiple tools into a single platform," and on deployment inside the customer's own perimeter for regulated buyers. Replacement means re-integrating a toolchain and re-certifying compliance. IP is the wrong label: only "16 issued patents and 25 pending patent applications," plus open-source licenses granting "broad permissions to use, copy, modify, and redistribute." The no-lock-in claim is the filing's own characterisation, footnoted to a Forrester study "commissioned by GitLab." | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | clear leader The FY2025 10-K makes exactly one unqualified rank claim and it is Display: 'We are the largest worldwide producer of glass substrates for flat panel displays', with only AGC Inc. and Nippon Electric Glass Co., Ltd. named as principal competitors. The second-strongest claim is Optical Communications' - 'We maintain a leadership position in the segment's principal product groups, which include carrier and enterprise networks' - asserted against Amphenol, Fujikura and its subsidiary America Fujikura Ltd., Sumitomo and Prysmian Group S.p.A. Those two lines carry the company: Optical Communications was 38% of total segment net sales in 2025 and Display 23%, and the segment table credits them with $1,048 million and $993 million respectively of the $2,747 million of reportable-segment net income. The band is a company-level judgment weighted to them, and it does not extend across the portfolio - Automotive claims only 'a strong market position', and Life Sciences describes itself as 'a leading developer, manufacturer and global supplier of laboratory products for over 110 years' while competing against the much larger Thermo Fisher Scientific Inc. and Danaher Corporation on $972 million of 2025 sales. | fast follower The 10-K positions GitLab against a leader rather than as one: "Our principal competitor is Microsoft Corporation, which owns GitHub." Competition reads from the challenger side, differentiating "from GitHub through flexible deployment options that work within enterprise security and compliance requirements, LLM neutrality with self-hosted gateway support" and an open core model. On AI it follows: Duo Agent Platform went "Generally available in January 2026," the last month of the fiscal year. What keeps it a follower rather than behind is cadence, "a new version of our software every month for 172 months in a row," plus a regulated-deployment franchise a SaaS-first rival does not cover. | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | moderate The FY2025 10-K shows prices being raised and sticking, and in the same breath shows what caps them. The results table puts gross margin at 36% of net sales in 2025 against 33% in 2024, and MD&A attributes the three-point gain to 'higher volume and the impact of actions taken by management to improve profitability, including raising prices, reducing costs and increasing productivity.' Display is the cleanest case: after resetting its core rate from 107 to 120 Japanese yen to the dollar, 'we implemented pricing actions in the second half of 2024', and 'The effects of the price increases on slightly higher volumes in 2025, compared to the prior period, substantially offset the impact of resetting the core rate.' The ceiling is disclosed in the same document: Optical Communications and Display are 'subject to pricing pressure', concentrated customers 'may possess substantial leverage in negotiating contractual obligations', and a risk factor warns that 'Increasing our prices to our customers may cause certain of our customers to push out, cancel or refrain from purchasing our products'. Price that holds on the back of rising volume, against customers that concentrated, is moderate rather than strong. | moderate FY2026 gross margin was 87% against 89%, with cost of revenue up $35.6 million "primarily due to an increase of $18.4 million in third party hosting costs for SaaS and cloud usage," and management expects SaaS and Duo mix to bring costs that "may adversely impact our gross margins." Strain is explicit: GitLab "may be required to reduce our prices," competitors "may offer their products and services at a lower price or for free," and it "implemented user limits on our free SaaS product." Power retained: Premium lists at $29 per user/month billed annually, and seats bundle $12 and $24 of GitLab Credits. But "A majority of our subscriptions are on a one-year period." | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | Corning is a materials company whose defence is a set of manufacturing processes it invented and then papered over with patents, and the FY2025 10-K is unusually explicit about where that defence holds and where it does not. It holds in Display, the one place the filing makes an outright rank claim - 'We are the largest worldwide producer of glass substrates for flat panel displays' - against only two named principal competitors, AGC Inc. and Nippon Electric Glass. The stated reason is process: a fusion process Corning invented, which it says 'is scalable and we believe it is the most cost-effective process for producing large size substrates', protected by patents and 'proprietary trade secrets'. It holds more loosely in Optical Communications, where the company claims 'a leadership position' and grounds it in 'large-scale manufacturing experience, fiber process, technology leadership and intellectual property', with 4,121 worldwide patents in that segment alone - but names Amphenol, Fujikura and America Fujikura, Sumitomo and Prysmian Group as principal competitors and says the landscape's 'industry consolidation, pricing pressure and competition for the innovation of new products' are 'likely to persist'. Those two lines carry the company: the filing puts Optical Communications at 38% of total segment net sales in 2025 and Display at 23%, and the segment table gives them $1,048 million and $993 million respectively of the $2,747 million of reportable-segment net income. Outside them the language weakens fast: Automotive claims 'a strong market position' against a single undivided list - 'Our principal competitors include NGK Insulators, Ltd., Ibiden Co., Ltd., AGC Inc. and LENS.'; Specialty Materials rests on capabilities and 'Brand recognition and loyalty, through well-known trademarks' against Schott, AGC, Nippon Electric Glass, Heraeus and JENOPTIK; and Life Sciences, at 6% of segment net sales and $61 million of segment net income on $972 million of sales, competes with Thermo Fisher Scientific, Danaher, Avantor and others while also facing 'competition from large distributors that have pursued backward integration or introduced private label products'. The demand side is currently the strongest part of the story rather than the moat: 2025 optical segment net sales rose 35% to $6,274 million, which the 10-K attributes to 'continued growth in our Enterprise business driven by strong demand for our Generative AI products, and in our Carrier business, driven by demand for datacenter interconnect products and fiber-to-the-home products'. That is a customer capex wave - the risk factors name 'fluctuations in telecommunication and hyperscale data center capital spending' as a risk to the very same business - landing on segments the company itself says are subject to pricing pressure, which is the honest reason this profile stops at narrow: Corning has a defended process franchise in glass and a strong but contested one in fiber, wrapped in segments where the filing claims no structural barrier at all. | GitLab sells a single-platform DevSecOps toolchain defended by workflow lock-in rather than intellectual property: a unified data model plus deployment flexibility, including single-tenant "Dedicated for Government with FedRAMP compliance," makes it hard to remove where data residency is contractual. The installed base expands: 118% Dollar-Based Net Retention, 10,682 Base Customers, 1,456 above $100,000 of ARR, 155 above $1.0 million (up 26%), over 70% of ARR from public sector and enterprise. The filing supplies the counterweight: "limited barriers to entry," Microsoft/GitHub as principal competitor, 16 issued patents. Retention (130 to 123 to 118, the 130 a cap), gross margin (89% to 87%) and a January 2026 AI launch point to compression at the commodity end. No source measures market share, so every share band is "unknown". | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | Corning sits a layer beneath the AI build-out, supplying the glass and fiber rather than the compute. The FY2025 10-K describes 'optical fiber, cable and connectivity solutions for advanced communications networks, such as fiber to the home and data centers, enabling artificial intelligence', and says 'the rapid acceleration of artificial intelligence ("AI") is driving strong demand for fiber and connectivity products inside and between data centers', citing purpose-built parts such as the SMF-28e Contour fiber, 'a 40% smaller fiber', and the Contour Flow Cable 'which can fit double the fiber into the same cable diameter'. It also sells into chipmaking, through HPFS Fused Silica, ULE Ultra-Low Expansion Glass and the EXTREME ULE Glass introduced in 2024 to 'support chip manufacturers in meeting the rapidly growing demand for advanced and intelligent technologies'. The exposure is already in the numbers: Optical Communications net sales rose 35% to $6,274 million in 2025, which the filing attributes first to 'continued growth in our Enterprise business driven by strong demand for our Generative AI products'. | GitLab sits at the software-tooling layer, not compute or models. It consumes third-party LLM capacity — marketing "LLM neutrality and support for self-hosted AI gateways, including air-gapped environments" — so it captures no model-layer economics and bears inference as COGS, visible in the $18.4 million rise in hosting costs. Its distinctive position is the regulated perimeter. | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.20 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |